ROSELLA Trial Offers New Insight Into Global Treatment Strategies for Ovarian Cancer: Brian Slomovitz, MD

In the second part of an interview with The American Journal of Managed Care^®, Brian Slomovitz, MD, an investigator on the phase 3 ROSELLA trial (NCT05257408), discusses how the combination of relacorilant plus nab-paclitaxel (Abraxane) compares with other available treatment options for patients with platinum-resistant ovarian cancer. He also underscores the importance of the ROSELLA trial's global scope.

Slomovitz is director of gynecologic oncology and cochair of the clinical research committee at Mount Sinai Medical Center in Miami Beach, Florida, as well as the clinical trial lead for uterine cancer for GOG Partners.

Watch part 1 of the interview to learn more about the trial's background, objectives, and results, which were presented this past Monday at the 2025 American Society of Clinical Oncology Annual Meeting.

This transcript was lightly edited; captions were auto-generated.

Transcript

How does the relacorilant plus nab-paclitaxel combination compare with other treatment options currently available for patients with platinum-resistant ovarian cancer?

When we compare these treatment options to others for patients with platinum-resistant ovarian cancer, that space represents an unmet need. Unfortunately, we've had a lot more negative trials than we've had positive trials. Coming up with a positive trial is really game-changing, right?

Now, we have the potential—if there's regulatory approval—the potential of giving patients an additional weapon in their arsenal, an additional option to fight against the cancer, to help with the improvement of progression-free survival [and] overall survival, which we need. We need to continue to have better agents for the management of this disease, and this is helping to fulfill that unmet need.

Could you explain the significance of the phase 3 ROSELLA trial being conducted on a global scale?

That's such an important question and such an important barrier that we've been able to overcome. The world's a smaller place. This is a trial that we did primarily between the GOG Partners group and ENGOT [European Society of Gynecological Oncological Trial Groups], which is the lead European clinical cooperative group. We've also used [in the rest of the world] other sites.

The fact that we're doing these studies with a global intent of doing what's best for our patients, as opposed to just the US study [or] just a European study, [means] we're able to get studies done quicker, we're able to make them more transferable across different populations, and we're able to really save effort and resources not having to duplicate trials. I think that should really not go unnoticed, the importance of global collaboration and doing trials like this.

The other thing is, in working with these global groups, I think equally as important is having a sponsor that's committed to the benefit of our patients. Corcept is the sponsor of the trial, and they've really invested a lot of time, energy, and resources in order for us to answer this question quickly and, without knowing, making an advantage for our patients.